BioAge Labs (NASDAQ:BIOA – Free Report) had its target price reduced by Citigroup from $21.00 to $20.00 in a report published on Wednesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.
A number of other equities research analysts have also weighed in on the stock. Weiss Ratings raised shares of BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. Roth Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of BioAge Labs in a research note on Wednesday, September 9th. Wall Street Zen lowered shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a report on Saturday, October 10th. UBS Group assumed coverage on shares of BioAge Labs in a research note on Sunday, October 11th. They issued a “neutral” rating and a $8.00 price objective on the stock. Finally, Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a report on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.00.
View Our Latest Report on BIOA
BioAge Labs Stock Performance
NASDAQ:BIOA opened at $4.28 on Wednesday. The stock’s 50-day moving average is $6.18 and its 200-day moving average is $14.77. BioAge Labs has a 1-year low of $4.24 and a 1-year high of $25.95.
BioAge Labs (NASDAQ:BIOA – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.05). The firm had revenue of $0.30 million during the quarter. BioAge Labs had a negative net margin of 1,253.60% and a negative return on equity of 31.42%. On average, research analysts forecast that BioAge Labs will post -2.59 earnings per share for the current year.
Hedge Funds Weigh In On BioAge Labs
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. a16z Capital Management L.L.C. bought a new position in shares of BioAge Labs in the 3rd quarter worth about $22,923,000. BlackRock Inc. acquired a new position in shares of BioAge Labs in the 2nd quarter valued at about $69,831,000. Jupiter Topco LLC bought a new stake in shares of BioAge Labs during the 2nd quarter valued at about $52,597,000. Janus Henderson Group PLC boosted its position in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after purchasing an additional 1,685,063 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of BioAge Labs during the 2nd quarter valued at about $8,686,000.
About BioAge Labs
BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.
Further Reading
- Five stocks we like better than BioAge Labs
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
